
ATOS
Atossa Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.8594
Open
0.850
VWAP
0.85
Vol
247.17K
Mkt Cap
109.63M
Low
0.8401
Amount
210.98K
EV/EBITDA(TTM)
--
Total Shares
125.76M
EV
43.63M
EV/OCF(TTM)
--
P/S(TTM)
--
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
--
--
-0.060
+20%
--
--
-0.057
-5.55%
--
--
-0.057
+13.34%
Estimates Revision
The market is revising No Change the revenue expectations for Atossa Therapeutics, Inc. (ATOS) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 28.13%.
EPS Estimates for FY2025
Revise Downward

-8%
In Past 3 Month
Stock Price
Go Up

+28.13%
In Past 3 Month
4 Analyst Rating

562.35% Upside
Wall Street analysts forecast ATOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATOS is 5.63 USD with a low forecast of 4.00 USD and a high forecast of 7.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy

562.35% Upside
Current: 0.850

Low
4.00
Averages
5.63
High
7.50

562.35% Upside
Current: 0.850

Low
4.00
Averages
5.63
High
7.50
Craig-Hallum
NULL
to
Buy
initiated
$4
2025-06-05
Reason
Craig-Hallum
Price Target
$4
2025-06-05
initiated
NULL
to
Buy
Reason
Craig-Hallum initiated coverage of Atossa Therapeutics with a Buy rating and $4 price target.
Craig-Hallum
Craig-Hallum
Buy
initiated
$4
2025-06-05
Reason
Craig-Hallum
Craig-Hallum
Price Target
$4
2025-06-05
initiated
Buy
Reason
As previously reported, Craig-Hallum initiated coverage of Atossa Therapeutics with a Buy rating and $4 price target. The firm points out that Z-endoxifen is a novel and potent SERM that can treat all stages of breast cancer. As the primary therapeutic metabolite of tamoxifen, Z-endoxifen is de-risked and has demonstrated differentiated efficacy and an advantageous safety profile in multiple clinical studies, Craig-Hallum argues, adding that Z-endoxifen development is focused on metastatic breast cancer, which offers the fastest path to market and can strategically support future expansion to early disease settings. The most notable opportunity is prevention, where Z-endoxifen's ability to avoid menopausal-like side effects can support uptake in a large TAM of over 10M women at high-risk of developing breast cancer in the U.S. The firm believes Atossa is undervalued and sees opportunity for share appreciation as Z-endoxifen gains further validation with readouts from neoadjuvant studies expected next year and design details for a Phase III metastatic breast cancer study and initiation expected by year-end 2025.
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$7 → $7.25
2025-04-21
Reason
Ascendiant Capital
Edward Woo
Price Target
$7 → $7.25
2025-04-21
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$7
2025-03-26
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$7
2025-03-26
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$7
2025-03-12
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$7
2025-03-12
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$7
2025-01-30
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$7
2025-01-30
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Atossa Therapeutics Inc (ATOS.O) is -3.61, compared to its 5-year average forward P/E of -6.42. For a more detailed relative valuation and DCF analysis to assess Atossa Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-6.42
Current PE
-3.61
Overvalued PE
-0.02
Undervalued PE
-12.82
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
+6.22%
-7.41M
Operating Profit
FY2025Q1
YoY :
+14.29%
-6.72M
Net Income after Tax
FY2025Q1
YoY :
-0.00%
-0.05
EPS - Diluted
FY2025Q1
YoY :
+26.87%
-5.97M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
1
9.9K
USD
Months
3-6
1
7.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
1
9.9K
USD
Months
3-6
1
7.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ATOS News & Events
Events Timeline
2025-05-14 (ET)
2025-05-14
08:19:50
Atossa Therapeutics reports results from Phase 2 EOP sub-study

2025-04-30 (ET)
2025-04-30
08:46:36
Atossa Therapeutics announces issuance of U.S. patent for (Z)-endoxifen

2025-04-29 (ET)
2025-04-29
08:47:13
Atossa Therapeutics proposes study aimed at reducing interval breast cancer

Sign Up For More Events
Sign Up For More Events
News
4.0
06-06BenzingaAscendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.5
4.0
06-05BenzingaThis Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
1.0
06-02NewsfilterAtossa Therapeutics to Present at the Jefferies Global Healthcare Conference
Sign Up For More News
People Also Watch

CURR
CURRENC Group Inc
1.850
USD
+12.12%

STKS
One Group Hospitality Inc
3.570
USD
+5.31%

SILC
Silicom Ltd
15.780
USD
0.00%

FONR
Fonar Corp
16.040
USD
+0.12%

MASS
908 Devices Inc
7.200
USD
+3.45%

CPHC
Canterbury Park Holding Corp
18.480
USD
0.00%

PRPL
Purple Innovation Inc
0.847
USD
+10.72%

MAXN
Maxeon Solar Technologies Ltd
4.210
USD
-0.47%

BSBK
Bogota Financial Corp
8.222
USD
0.00%

FNWB
First Northwest Bancorp
7.850
USD
0.00%
FAQ

What is Atossa Therapeutics Inc (ATOS) stock price today?
The current price of ATOS is 0.85 USD — it has increased 0.12 % in the last trading day.

What is Atossa Therapeutics Inc (ATOS)'s business?

What is the price predicton of ATOS Stock?

What is Atossa Therapeutics Inc (ATOS)'s revenue for the last quarter?

What is Atossa Therapeutics Inc (ATOS)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Atossa Therapeutics Inc (ATOS)'s fundamentals?

How many employees does Atossa Therapeutics Inc (ATOS). have?
